Molbio Diagnostics Ltd (MOLBIO) — Board Meeting | 5 September 2026

· BSE 🟡 Notable Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Board approved unaudited Q1 FY2027 financial results and authorized KMPs to determine materiality of events.
🔄 What Changed
Approved unaudited standalone and consolidated financial results for Q1 FY2027; empowered KMPs to assess materiality of future events.
💡 Investor Takeaway
Shareholders now have timely access to approved quarterly financials and a structured process for timely material event disclosures.

Molbio Diagnostics announced approval of unaudited standalone and consolidated financial results for Q1 FY2027 ending June 30, 2026, following board approval and limited auditor review. The board also empowered key managerial personnel to assess materiality of future events and disclose them promptly under SEBI regulations.

📄 View Original Announcement (PDF)

About Molbio Diagnostics Ltd (MOLBIO)

Healthcare · Healthcare · Listed on BSE

Market Cap: ₹16,255.48 Cr

View full MOLBIO stock details →

📡 Get AI alerts when MOLBIO files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track MOLBIO — Free

📊 More MOLBIO filings

See all MOLBIO filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when MOLBIO files new disclosures

Track MOLBIO filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track MOLBIO — Free

Free account · 2 AI queries/day